Latest News
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Biotech Sector Roundup – Investor Roundtable Video
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we focus on the biotech sector and discuss three interesting companies: Kezar Life Sciences (KZR.Q), BioMarin Pharmaceutical (BMRN.Q) and Medexus Pharmaceutical (MDP.T).
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on BMRN.Q, KZR.Q, MDP.T
Medexus Pharmaceuticals (MDP.T) – Three Minute Hits Video
Medexus Pharma (MDP.T) – Investor Roundtable Video #3
Medexus Pharma (MDP.T) – Three Minute Hits Video
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E102
Medexus Pharma’s (MDP.T) specialty pharma investment value on the rise